| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Turkey Tail (Trametes versicolor) Key Compounds: Polysaccharide-K (PSK, also known as Krestin) and polysaccharide peptide (PSP). -Toll-Like Receptor (TLR) Activation -Increased NK cell and cytotoxic T-cell activities -Upregulation of IFN-γ Turkey Tail (Trametes versicolor) — a medicinal polypore mushroom, formerly widely cited as Coriolus versicolor, used as a food-derived medicinal mushroom and source of protein-bound polysaccharides with immunomodulatory activity. It is formally classified here as a food source / medicinal mushroom rather than a single defined drug. Common abbreviations include TV or Tv; its principal standardized derivatives are polysaccharide-K (PSK; Krestin) and polysaccharopeptide (PSP). PSK is a heterogeneous protein-bound β-glucan-rich preparation derived from cultured T. versicolor mycelium, while PSP is a related but compositionally distinct preparation. Clinical evidence applies primarily to standardized PSK rather than to generic Turkey Tail powders or extracts. PSK has been used as an adjunctive cancer therapy in Japan, whereas Turkey Tail and PSK are not FDA-approved cancer treatments in the United States. Primary mechanisms (ranked):
Bioavailability / PK relevance: PSK and PSP are heterogeneous, relatively high-molecular-weight protein-polysaccharide mixtures rather than conventional small molecules. Animal radiolabel studies indicate that a fraction of orally administered PSK can be absorbed or distributed beyond the gastrointestinal tract, but much of the dose appears to undergo gastrointestinal degradation or metabolism. Human systemic pharmacokinetic data remain limited. Biological activity after oral administration may therefore reflect gastrointestinal, microbiome and mucosal/immune interactions in addition to direct systemic exposure. In-vitro vs systemic exposure relevance: Direct tumor-cell inhibition is often demonstrated using isolated PSP fractions, PSK-related preparations or individual Turkey Tail constituents at concentrations in the tens to hundreds of micrograms per millilitre. Equivalent free systemic concentrations following oral mushroom or PSK administration have not been established in humans and may not be achievable. Direct cytotoxic mechanisms should therefore be considered preclinical and preparation-dependent; immune modulation has substantially stronger biological and clinical plausibility for orally administered PSK. Clinical evidence status: RCT / adjunct use for standardized PSK, with historical randomized studies and meta-analyses reporting improved disease-free or survival outcomes in selected gastric, colorectal and other cancers when PSK was added to contemporaneous chemotherapy. Evidence for whole Turkey Tail mushroom preparations is much weaker and includes small human studies, including a Phase I breast-cancer study showing tolerability and immune effects. A Phase II pilot study of Turkey Tail extract in ER-positive/HER2-negative breast cancer is ongoing. Evidence does not support replacing standard oncologic therapy with Turkey Tail. Product standardization is a major translational limitation because commercially available mushroom powders, mycelial products, PSP and pharmaceutical PSK are not biologically interchangeable. Turkey Tail Mechanistic Profile
|
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:306 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid